Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 6, 2006, Pages 1605-1609

  Levin, J I ^a   Chen, J M ^a   Laakso, L M ^a   Du, M ^a   Schmid, J ^a   Xu, W ^b   Cummons, T ^b   Xu, J ^a   Jin, G ^a   Barone, D ^c   Skotnicki, J S ^a  

^a WYETH RESEARCH   (United States)

^b PFIZER INC   (United States)

^c AMGEN INC   (United States)

Author keywords

Rheumatoid arthritis; Sulfonamide: hydroxamate; TACE inhibitor; Thiomorpholine

Indexed keywords

COLLAGEN; COLLAGENASE 3; INTERSTITIAL COLLAGENASE; THIOMORPHOLINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR;

ALKYLATION; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MITSUNOBU REACTION; NONHUMAN; RAT; RHEUMATOID ARTHRITIS; X RAY CRYSTALLOGRAPHY;

ACETYLENE; ADAM PROTEINS; ADMINISTRATION, ORAL; ALKYNES; ANIMALS; ARTHRITIS; CACO-2 CELLS; COLLAGEN; COLLAGENASES; CRYSTALLOGRAPHY, X-RAY; DISEASE MODELS, ANIMAL; DOGS; ENZYME INHIBITORS; HAPLORHINI; HUMANS; HYDROXAMIC ACIDS; LIPOPOLYSACCHARIDES; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 13; MICE; MOLECULAR STRUCTURE; MORPHOLINES; PROPANOLS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 32044455976     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.12.020     Document Type: Article

References (30)

1. R.C. Newton, and C.P. Decicco J. Med. Chem. 42 1999 2295
2. M.A. Palladino, F.R. Bahjat, E.A. Theodorakis, and L.L. Moldawer Nat. Rev. Drug Disc. 2 2003 736
3. J.S. Skotnicki, and J.I. Levin Ann. Rep. Med. Chem. 38 2003 153
4. R.C. Newton, K.A. Solomon, M.B. Covington, C.P. Decicco, P.J. Haley, S.M. Friedman, and K. Vaddi Ann. Rheum. Dis. 60 2001 iii25
5. M.L. Moss, and J. Bartsch Biochemistry 43 2004 7227
6. M. Grootveld, and M.F. McDermott Curr. Opin. Invest. Drugs 4 2003 598
7. J.J.-W. Duan, Z. Lu, C.-B. Xue, X. He, J.L. Seng, J.J. Roderick, Z.R. Wasserman, R.-Q. Liu, M.B. Covington, R.L. Magolda, R.C. Newton, J.M. Trzaskos, and C.P. Decicco Bioorg. Med. Chem. Lett. 13 2003 2035
8. A. Trifilieff, C. Walker, T. Keller, G. Kottirsch, and U. Neumann Br. J. Pharmacol. 135 2002 1655
9. G. Beck, G. Bottomley, D. Bradshaw, M. Brewster, M. Broadhurst, R. Devos, C. Hill, W. Johnson, H.-J. Kim, S. Kirtland, J. Kneer, N. Lad, R. Mackenzie, R. Martin, J. Nixon, G. Price, A. Rodwell, F. Rose, J.-P. Tang, D.S. Walter, K. Wilson, and E. Worth J. Pharmacol. Exp. Ther. 302 2002 390
10. For excellent discussions of MMP inhibition and related side effects, see: J.T. Peterson Heart Fail. Rev. 9 2004 63
11. R. Renkiewicz, L. Qiu, C. Lesch, X. Sun, R. Devalaraja, T. Cody, E. Kaldjian, H. Welgus, and V. Baragi Arthritis Rheum. 48 2003 1742
12. Y. Yoshihara, H. Nakamura, K. Obata, H. Yamada, T. Hayakawa, K. Fujikawa, and Y. Okada Ann. Rheum. Dis. 59 2000 455
13. Y.T. Konttinen, M. Ainola, H. Valleala, J. Ma, H. Ida, J. Mandelin, R.W. Kinne, S. Santavirta, T. Sorsa, C. Lopez-Otin, and M. Takagi Ann. Rheum. Dis. 58 1999 691
14. J.M. Chen, G. Jin, A. Sung, and J.I. Levin Bioorg. Med. Chem. Lett. 12 2002 1195
15. J.I. Levin, J.M. Chen, L.M. Laakso, M. Du, X. Du, A.M. Venkatesan, V. Sandanayaka, A. Zask, J. Xu, W. Xu, Y. Zhang, and J.S. Skotnicki Bioorg. Med. Chem. Lett. 15 2005 4345
16. T. Tsukida, H. Moriyama, Y. Inoue, H. Kondo, K. Yoshino, and S. Nishimura Bioorg. Med. Chem. Lett. 14 2004 1569
17. H. Moriyama, T. Tsukida, Y. Inoue, K. Yokota, K. Yoshino, H. Kondo, N. Miura, and S.-I. Nishimura J. Med. Chem. 47 2004 1930
18. Bender, S.L.; Melnick, M. J. U.S. Patent 5,753,653, 1998; Chem. Abstr. 1998, 129, 16140.
19. J.I. Levin, M.T. Du, and K. Park Synthetic Commun. 34 2004 2773
20. M.A. Letavic, M.Z. Axt, J.T. Barberia, T.J. Carty, D.E. Danley, K.F. Geoghegan, N.S. Halim, L.R. Hoth, A.V. Kamath, E.R. Laird, L.L. Lopresti-Morrow, K.F. McClure, P.G. Mitchell, V. Natarajan, M.C. Noe, J. Pandit, L. Reeves, G.K. Schulte, S.L. Snow, F.J. Sweeney, D.H. Tan, and C.H. Yu Bioorg. Med. Chem. Lett. 12 2002 1387
21. Laakso, L. M.; Levin, J. I.; Du, M.; Jin, G.; Cowling, R.; Skala, S.; Cummons, T.; Xu, J.; Barone, D.; Skotnicki, J. S. Abstracts of Papers, 226th National Meeting of the American Chemical Society, New York, NY, Sept 7-11, 2003; MEDI 116. Manuscript in preparation.
22. H. Weingarten, and J. Feder Anal. Biochem. 147 1985 437
23. 50 determinations were calculated from a 4-parameter logistic fit of the data within a single experiment.
24. G. Jin, X. Huang, R. Black, M. Wolfson, C. Rauch, H. McGregor, G.A. Ellestad, and R. Cowling Anal. Biochem. 302 2002 269
25. For a description of all cell and in vivo assays, see: Y. Zhang, J. Xu, J. Levin, M. Hegen, G. Li, H. Robertshaw, F. Brennan, T. Cummons, D. Clarke, N. Vansell, C. Nickerson-Nutter, D. Barone, K. Mohler, R. Black, J. Skotnicki, J. Gibbons, M. Feldman, P. Frost, G. Larsen, and L.-L. Lin J. Pharmacol. Exp. Ther. 309 2004 348
26. B. Lovejoy, A.R. Welch, S. Carr, C. Luong, C. Broka, R.T. Hendricks, J.A. Campbell, K.A.M. Walker, R. Martin, H. Van Wart, and M.F. Browner Nat. Struct. Biol. 6 1999 217
27. PDB deposition number: 2A8H.
28. J.I. Levin, and M.T. Du Drug Design Discov. 18 2003 123
29. Zhang, Y.; Xu, J.; Udata, C.; McDevitt, J.; Cummons, T.; Zeng, C.; Sun, L.; Zhu, Y.; Gibbons, J.; Skotnicki, J.; Lin, L.-L.; Levin, J. Scientific Abstracts, Annual European Congress of Rheumatology, Vienna, Austria, June 8-11, 2005; Abstract 1812.
30. Hegen, M.; Zhang, Y.; Levin, J.; Xu, J.; Cummons, T.; Harding, K.; Sheppard, B. J.; Leach, M. W.; Lin, L.-L.; Gibbons, J.; Skotnicki, J.; Nickerson-Nutter, C. L. Scientific Abstracts, Annual European Congress of Rheumatology, Vienna, Austria, June 8-11, 2005; Abstract 157.